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This is a paper reviewing the National Health Service (NHS) agenda in relation to the use of Negative Pressure Wound Therapy
(NPWT) in chronic wound management and assesses the evidence behind it, its cost eﬀectiveness and the outcome it has on
patients’ satisfaction and life style. Multiple studies over the last 10 years looking at clinical eﬃcacy of NPWT with its cost
eﬀectiveness and the implementation of this service in the UK were reviewed. NPWT has showed a reasonable body of evidence
to support its usage in chronic wounds with potential positive outcomes on ﬁnance and patients’ satisfaction. However, the NHS
system shows signiﬁcant variations in the availability and implementation of this useful tool, depending on care providers and
resources availabilities. The paper concluded that the NPWT can be a useful source of cutting down costs of chronic wound
managements and saving money by its eﬀect on expediting wound healing, which can address a part of the ﬁnancial crises facing
theNHS,however,hastobeconsideredaccordingtospeciﬁccaseneeds.Thereshouldalsobeanationalstandardfortheavailability
and indication of this tool to assure equal opportunities for diﬀerent patients in diﬀerent areas in the country.
1.Introduction
The National Health Service (NHS) represents itself as a
unique system providing healthcare for all regardless of
ﬁnancial status. At the moment, it is reaching the point that
patients’ demands are overcoming NHS resources causing
conﬂict in-between. Coombes [1] debated the best future for
the NHS whether best to stay free at the point of use or
be privatized. Moreover, the Secretary of State for Health
proposedtoabolishtheNHSinEngland[2].BuntandHarris
[3] claimed that the NHS needs to save £15 billion to £20
billionoverthenextfewyearsandarguedthatsigniﬁcantsav-
ings can be achieved through radical patient-centred service
redesign and more eﬀective approaches to public behaviour
change. The uses of ﬁnancial rewards and pay-for-perfor-
mance programs have been introduced to improve cost-
eﬀectiveness and quality of care, yet there remains scant
evidence of the success of such initiatives from an economic
perspective [4]. The focus on national targets in healthcare
delivery has changed; the new focus is one of quality, innova-
tion,productivity,andprevention(QIPP)programme[5,6].
This has been described as “the new landscape in which we
operate” [7].
Chronic wound management represents a considerable
burden on health services and requires considerable man-
power, frequent specialist consultation, and adjunct thera-
pies; an important example of these adjunct therapies is the
negative pressure wound therapy (NPWT), which was sug-
gested to oﬀer an important option for the advanced man-
agement of many wound types [8–10]. Manpower constitute
a great portion of this cost. In their national UK audit, Drew
et al. [11] suggested that nurses time accounts for 33–41%
of the total cost of wound care. On the other hand, chronic
wounds can also aﬀect patients’ ability to function in their2 Plastic Surgery International
environment, causing ﬁnancial, social, and psychological
consequences as well as aﬀecting patients’ Quality of Life
(QoL) [12–14].
Patient’s safety, eﬀectiveness, and experience have been
identiﬁed as quality domains in the NHS white paper [15].
It aims to put patients at the heart of the NHS by oﬀering
greater choice and control of services. The key is shared deci-
sion making, summed up by the phrase “no decision about
me without me.” At the same time, it is recognised that the
quality of health care cannot be allowed to decline; therefore,
itmustbesubjecttocontinuousimprovement.Thechallenge
faced by the NHS and practitioners within it is to improve
the quality of care in an environment where the available
resources are unlikely to keep pace with increasing demand
[16]. Shorney [15] suggested that by using metrics, wound
care services will be able to quantify the eﬀectiveness of care
provision and use this to argue for future resources and
funding of such services.
This paper will consider the NHS agenda in relation to
the use of NPWT in wound management, its cost eﬀective-
ness, its eﬀects on patients’ life, and healthcare demands and
available resources.
2. Evidence behind NPWT Efﬁcacy
NPWT beneﬁts include rapid wound granulation, epithelial-
isation and contraction [17], reduction of dressing changes
[18], reduced infection risk [19], reduced treatment costs
[20], control of exudate [21], concurrent rehabilitation [22],
and better patient tolerance [23].
The eﬃcacy of NPWT was initially described by Moryk-
was et al. [24] and Morykwas [25]. Philbeck et al.’s [26]
pioneeringworkstudied1,032homehealthcarepatientswith
1,170 wounds that failed to respond to previous interven-
tions and were subsequently treated with NPWT and con-
cluded NPWT to be eﬃcacious and economical treatment
modality. The conventional therapy cost was an estimation
based on a study from 6 years before [27], which does not
represent an accurate estimation as they did not allow for
inﬂation.
Severalstudieshavefollowedandidentiﬁedfasterhealing
times with NPWT when compared to moisturized saline
gauze [28–32]. However, moisturized gauze is not an appro-
priate comparison where other modern dressings could have
been compared to NWPT.
M o u e se ta l .[ 18] examined the total costs (hospitaliza-
tion, nursing, and material) of 54 wounds. The mean was
in favour of NPWT; NPWT had signiﬁcantly higher material
expenses (P<0.0001), but signiﬁcantly lower nursing ex-
penses (P<0.043). Schwein et al. [33]p e r f o r m e dar e t -
rospective analysis of 2288 pressure ulcers (PUs) in home
health settings to examine both clinical and economic
beneﬁts of NPWT. A matched cohort of 60 NPWT patients
showed lower rates of general hospitalisation (P<0.05),
wound problems (P<0.01), and emergency admission (P =
0.01).
Llanos et al. [34] RCT on 60 patients with burns con-
cluded improved skin graft take (P = 0.001) and shorter
hospitalisation (P = 0.01) with NPWT. Blume et al. [35]
conducted the largest multicentre RCT with 342 patients
with diabetic foot ulcers (DFUs) comparing NPWT to
alginate and hydrogel dressings and concluded that NPWT
group had faster healing (P = 0.007), reduced secondary
amputations (P = 0.035), and shorter hospitalisation period
(89.5% versus 95.3%); however, it was not statistically signi-
ﬁcant. Trueman [36] pointed that the reduction of unnec-
essary hospital admissions opened the scope for the use
smaller NPWT pumps allowing early patient discharge and
management in the community. Potential beneﬁts include
freeing up hospital beds, reducing costs, improved patient
satisfaction, and reduced hospital readmissions and nosoco-
mial infections.
Meta-analysis is a principal method of cost-eﬀectiveness
analysis; however, the heterogeneity of such patients treated
with NPWT makes it diﬃcult to compare between diﬀerent
studies [37]. In their systematic review on NPWT, Vikatmaa
et al. [38] studied 14 randomised clinical trials (RCTs) which
included patients with PUs (two), posttraumatic wounds
(three), DFUs (four), and miscellaneous chronic wounds
(ﬁve). They reported that only two trials were classiﬁed as
high quality studies. In all trials NPWT was at least as effect-
ive and in some cases more eﬀective than the control treat-
ment. They concluded NPWT to be a safe treatment, and
serious adverse events have been rarely reported. Ubbink
et al. [39] reviewed NPWT in 13 RCTs and concluded
presence of a supportive evidence for the use of NPWT in
the treatment of wounds.
These studies reﬂect an evidence that NPWT is eﬃcient
in treating wounds with improved clinical outcomes and
should stimulate the healthcare system to provide such ser-
vices and prevent it being obstructed by ﬁnancial constrains.
This motivated national and international committees to
develop NPWT guidelines in wound care, such as the
National Institute for Health and Clinical Excellence [40]
report on NPWTs in open abdomen, which commented
“The use of NPWT was initially conﬁned to secondary care
but this therapy is now provided in primary care, enabling
earlier discharge for patients” meeting the targets of the
DoH QIPP programme right care paper [41]. Williams [42]
developed a practical document to support healthcare pro-
fessionals and managers in developing a managed NPWT
service to reduce costs and be able to access the service when
needed and spare time and eﬀort spent sourcing equipment
before. Birke-Sorensen et al. [43] suggested the importance
of developing an international consensus for NPWT recom-
mendations and treatment variables.
3. NPWT Cost Analysisand
Effect on Patients QoL
Three studies from 2006 [21, 44, 45]r e p o r t e di m p r o v e d
patients’ QoL with NPWT applied to chronic wounds.
Braakenburg et al.’s [21] blinded RCT (n = 65) compared
NPWT to dressings (hydrocolloids, alginate, acetic acid,
and sodium hypochlorite), although acetic acid and sodium
hypochlorite are not recommended wound care products.
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and lesser time investment (P = 0.3a n dP = 0.83, P = 0.04,
resp.). Total costs were in favour of the dressings group, how-
ever, insigniﬁcant (P = 0.09). Although NPWT instruments
and dressings are more expensive, their longer application
on wounds and less frequent changing will reduce the total
cost and the labour power and positively impacting on
productivity.Vuerstaeketal.’s[44]p r ospecti v eR CT(n = 60)
reported quicker healing, faster wound preparation for graft-
ing, and reduced costs with NPWT (P = 0.001, P = 0.005,
P = 0.001, resp.); the major part of this cost diﬀerence was
due to higher personnel costs and longer hospital stay in the
dressings group caused by the slower healing. Both groups
showed signiﬁcant increase in patients’ QoL and decrease in
pain scores. Augustin and Zschocke [45]s t u d y( n = 176)
measured outcomes before and after NPWT and reported
signiﬁcant (P<0.001) increase in QoL and higher satisfac-
tion.Itisveryimportanttoincludethepatientinthedecision
making of the available treatment options as highlighted in
the NHS agenda: “Shared decision-making will become the
norm: no decision about me without me” [46]. Patients’
involvement is an important point highlighted by the Right
Care paper by the DoH [41] QIPP programme.
Searle and Milne’s [47] literature review of the cost anal-
yses of NPWT concluded that there is a strong evidence of
NPWT for cost savings compared to conventional therapies.
Abbotts[48]reportedimprovedwoundhealinginallbutone
patient(n = 12).Concernsofmostpatients weretheexudate
smell from the canister, embarrassment, noise, and pain. On
the other hand, these patients used to prepare the dressings
before the arrival the nurse and they became conﬁdent
with troubleshooting; they described patching air leaks and
unblocking tubes. Changing dressings less frequently should
reduce both exposure to contaminants and disruption to the
wound healing process. Also, this level of patients’ engage-
ment can reduce time and eﬀort spent by the staﬀ and save
the NHS further costs and free up nurses for other activities,
leading to increased service productivity with a positive
impact on the patient experience.
This represents an important aspect of the current DoH
QIPP programme [49] to provide high level of care and yet
save money by transforming community services. Dowsett
et al.’s [16] cost analysis examined the savings made by
implementation of the NPWT service in the community on
255 patients between 2009 and 2011. The cost per in-patient
episode has been calculated comparing it to the secondary
care; they concluded that by treating the patient in the com-
munity, there was cost saving of £4814 per patient. On the
larger scale of wound care service delivered in the UK, the
total savings could be very signiﬁcant and address a large
aspect of the current ﬁnancial deﬁcit in the NHS as well as
help focusing the care of the patient closer to their home.
4. NPWT Demands andNHS Supplies
Achieving a balance between the NHS national agenda and
patients most favourable outcomes is the key point. Mis-
match between NHS demand and supply has always been a
worry for care providers. The recent report by Lord Darzi
[50] on transforming community services has followed his
previous report [51] on providing high quality of care for
all patients. He emphasised the importance of tissue viability
and wound care in the community. He provided an example
of “evidence-based practice” using NPWT and stressed on
“getting the basics right every time”. This report remains a
potential stimulus for the government to consider this issue
as a high priority. White [52] claimed that the government
had a low proﬁle on tissue viability and wound care with
developing risk on tissue viability nurses (TVNs) jobs due to
ﬁnancialpressureandurgedtheprimarycarecommissioners
to pay attention to the broad spectrum of wound care. The
government started addressing this issue over the last 4 years,
withthemajorfocusonpressureulcersproblem,andalready
pledged to increase the inﬂuence of the nurses taking lead
on this [53]. However, due to loss of collaboration between
healthcare professionals, this may lead to clinical nurse
specialist feeling “constrained” [54, 55].
The use of NPWT in home health settings remains rela-
tively limited due to ﬁnancial restrictions [16, 56, 57]. Some
healthcare purchasing authorities in the UK provide a list
of speciﬁc wounds where they consider NPWT is indicated
[42], which sometimes limit individual decision making and
canrepresentacollisionbetweenNHSdemandsandsupplies
[58]. This may create some challenges where issues such
as accountability, shared resources, and assurance of care
quality should be considered, including clinically eﬀective,
personally tailored, and safe level of service [59].
Harvard and Weston [60] reported that some healthcare
professionals had diﬃculty in obtaining funding for some
of the newer technologies, including NPWT. They examined
the NHS tissue viability services in 173 trusts in England
and concluded variable results, ranging from no dedicated
provision (8.6%) to multidisciplinary tissue viability teams
(31.9%). Only 33.6% of the trusts had outpatient NPWT
service, with the other 66.4% having to admit patients for
NPWT.Moreover,somehealthcareprofessionalscomplained
of a complicated approach to these services; 8% of the trusts
reported problems obtaining NPWT funding. This ﬁnancial
and resources availability burden to manage patients with
outpatients NPWT machines can cause signiﬁcant inpatient
costs, nosocomial infection risk, and ﬁnancial and psy-
chological concerns for patients themselves. 50% of the
trusts claimed underfunding for their TVN and NPWT and
compromising their outpatient NPWT facilities. This means
that patients will receive diﬀerent treatment levels depending
on their post code and trust’s catchment area, which may
raise ethical inequity issues. Also, NPWT purchasing activity
is predominated by NHS Trusts (devices) and NHS Supply
Chain (consumables), a process that may compromise ser-
vice delivery.
Searle and Milne [47] reported that the growing pressure
on hospital beds has increased the use of NPWT in com-
munity settings. A recent publication from the DoH [61, 62]
suggested that as a result of advances in tissue viability, more
complex wound care can now be provided in the community
settingandtherapiessuchasNPWTshouldbecommonplace
and emphasised that tissue viability professionals should be
appointed to direct service provision with high standards. A
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[63] identiﬁed several issues related to the implementation
and continuation of NPWT in primary care; this included
untimely patients referrals requiring NPWT, lack of training
of community patients and staﬀ, complicated community
funding pathways, and lack of co-ordination between sec-
ondary and primary care.
Adapting the NPWT use is a major step forward; NPWT
is often perceived to be more expensive than advanced
wound care; however, this perception may be based more on
unit price considerations than on a comparison of the total
treatment cost [63]. It is important to remember that there
may be some cases where a new treatment is beneﬁcial clin-
ically and ﬁnancially on the long term but is unaﬀordable to
initialise the starting cost.
5. Conclusion
The NHS is trying to save money and yet provide the same
qualityofcare.Woundmanagementisapotentialﬁeldwhere
this could be addressed, through a wider use of NPWT.
There is a substantial body of clinical and economic evi-
dence supporting NPWT in wound management, including
early discharge and faster healing, fewer readmissions, better
patients’ QoL, and improved cost eﬀectiveness meeting the
DoH QIPP agenda. The type and quality of studies are
mixed: alongside RCTs, there is evidence in real world
clinical practice, in the form of retrospective clinical studies.
However, further controlled RCTs are encouraged as well as
recognition of personal clinical experiences. Beyond tech-
nical failures in applying the dressing, NPWT is safe and
well tolerated by patients. However, it is essential to provide
training and education and monitor its use in day-to-day
practice. NPWT has evolved from large devices to smaller,
more portable devices, which can allow a smoother transi-
tion from hospital to community. Currently, there is a sub-
stantial evidence to support lack of NPWT for both primary
and secondary care due to ﬁnancial constrains, which con-
ﬂictswith the targets set by the DoH and QIPPreports. More
focusedattentionbytheNHSiswarrantedforsuchserviceto
be rewarding clinically, ﬁnancially, and socially. All patients
should be assessed on an individual basis and have equality
impact and risk assessments to ensure that every patient has
the opportunity to beneﬁt from NPWT, which is a valuable
addition, if used appropriately to speciﬁc patients’ case and
health care provider experience.
These studies and others have provoked national and
international committees to develop NPWT wound care
guidelines. This should encourage the NHS to conduct stud-
ies to validate these results with implemented local evalua-
tions and audits to support widespread adoption of NPWT
in national wound care.
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